Can Immunotherapy Replace Surgery for Stomach Cancer? Can Immunotherapy Replace Surgery for Stomach Cancer?
In a small study, just over half (59%) of patients who had combination immunotherapy showed no sign of tumor on preoperative endoscopy.Medscape Medical News (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - January 27, 2022 Category: Surgery Tags: Hematology-Oncology News Source Type: news

Fiber in diet linked to cancer immunotherapy response
People who ate a high-fiber diet and didn ’t use over-the-counter probiotic supplements lived the longest after immunotherapy for melanoma. (Source: NIH Research Matters)
Source: NIH Research Matters - January 25, 2022 Category: Research Source Type: news

Combo Immunotherapy Ups Survival in Advanced Liver Cancer
Overall survival, but not progression - free survival, improved with tremelimumab plus durvalumab versus sorafenib for unresectable HCC (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - January 24, 2022 Category: Cancer & Oncology Tags: Gastroenterology, Oncology, Pharmacy, Conference News, Source Type: news

Adding Immunotherapy to Chemo Ups Survival in Advanced Biliary Tract Cancer
Overall survival, progression - free survival prolonged in those receiving durvalumab versus placebo in addition to gemcitabine and cisplatin (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - January 24, 2022 Category: Cancer & Oncology Tags: Gastroenterology, Oncology, Pharmacy, Conference News, Source Type: news

Peanut Oral Immunotherapy at Younger Age Ups Desensitization in Children
FRIDAY, Jan. 21, 2022 -- For young children with peanut allergy, initiation of peanut oral immunotherapy is associated with an increase in desensitization and remission, according to a study published in the Jan. 22 issue of The Lancet. Stacie M.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 21, 2022 Category: Pharmaceuticals Source Type: news

Peanut Oral Immunotherapy Works in Toddlers: IMPACT Trial Peanut Oral Immunotherapy Works in Toddlers: IMPACT Trial
After 2.5 years of peanut oral immunotherapy, 71% of toddlers could safely consume 17 peanuts, and more than 1 in 5 maintained this protection even after stopping treatment for 6 months.Medscape Medical News (Source: Medscape Pediatrics Headlines)
Source: Medscape Pediatrics Headlines - January 21, 2022 Category: Pediatrics Tags: Allergy & Clinical Immunology News Source Type: news

CT radiomics, machine learning predict melanoma survival
The combination of CT radiomics and machine learning can predict survival o...Read more on AuntMinnie.comRelated Reading: Radiomics model distinguishes vertebral compression fractures CT radiomics helps to predict pancreatic cancer metastases PET/CT predicts survival outcomes in immunotherapy patients PET tracer proves effective for assessing immunotherapy CT radiomics helps predict spontaneous intracerebral hemorrhage (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - January 21, 2022 Category: Radiology Source Type: news

Children can get over peanut allergies by slowly increasing their exposure, study suggests
US researchers found nearly three quarters of children with the allergy given immunotherapy avoided a reaction when given the equivalent of 16 peanuts after two-and-a-half years. (Source: the Mail online | Health)
Source: the Mail online | Health - January 20, 2022 Category: Consumer Health News Source Type: news

Study: Starting peanut immunotherapy at age 3 or younger can resolve allergies
Most young children with peanut allergies treated with immunotherapy achieved desensitization within 2 1/2 years, a study published Thursday by the Lancet found. (Source: Health News - UPI.com)
Source: Health News - UPI.com - January 20, 2022 Category: Consumer Health News Source Type: news

Oral immunotherapy induces remission of peanut allergy in some young children
NIH trial found experimental therapy also reduced most children ’s sensitivity to peanut. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - January 20, 2022 Category: American Health Source Type: news

Phenotypic and Functional Characterization of CAR T Cells
How advanced flow cytometry and live-cell analysis are accelerating immunotherapy research. (Source: The Scientist)
Source: The Scientist - January 19, 2022 Category: Science Tags: The Marketplace Source Type: news

Uncovering the Cancer Proteome with Automated Western Assays
A robust, automated western blot system accelerates immunotherapy development. (Source: The Scientist)
Source: The Scientist - January 19, 2022 Category: Science Tags: The Marketplace Source Type: news

Immunotherapy Combination Shown to Benefit Some Patients with Non-Small Cell Lung Cancer Resistant to Single Immunotherapy
A combination of two drugs that open the floodgates to an immune system attack on cancer curtailed tumor growth in some patients with non-small cell lung cancer (NSCLC) that was resistant to a single immunotherapy agent, results from a recent clinica (Source: BWH News)
Source: BWH News - January 13, 2022 Category: Hospital Management Source Type: news

CBMG Receives FDA Regenerative Medicine Advanced Therapy and Fast Track Designations for Bi-Specific Anti-CD19/CD20 CAR-T Cell Therapy for Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
ROCKVILLE, Md., Jan. 12, 2022 -- (Healthcare Sales & Marketing Network) -- Cellular Biomedicine Group Inc. (CBMG or the "Company"), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today ann... Biopharmaceuticals, Regenerative Medicine, Oncology, FDA Cellular Biomedicine Group, CAR-T (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 12, 2022 Category: Pharmaceuticals Source Type: news

NCI Opens New Immunotherapy Clinical Trial for Mesothelioma
This study offers a reasonable chance of benefit. It would be nice to see if these patients again respond to immunotherapy.” The FDA approved Opdivo and Yervoy, an immunotherapy combination, for first-line treatment of pleural mesothelioma in 2020. It was the first new systemic approval in more than 16 years. However, it only increased the median overall survival time from 14.1 months to 18.1 months, when compared to standard chemotherapy. Find Immunotherapy Clinical Trials ...
Source: Asbestos and Mesothelioma News - January 4, 2022 Category: Environmental Health Authors: Chris Elkins Source Type: news